Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma in Adults Following Prior Vascular Endothelial Growth Factor Targeted Therapy: Clinical Trial Evidence and Experience

Therapeutic Advances in Urology - United States
doi 10.1177/1756287217748867
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

SAGE Publications

Related search

Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Clinical Experience With Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2015English

Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2007English

Brain Complete Response to Cabozantinib Prior to Radiation Therapy in Metastatic Renal Cell Carcinoma

Case Reports in Urology
2019English

First-Line Vascular Endothelial Growth Factor Inhibitors for Advanced Renal Cell Carcinoma and the Impact of New Agents Entering the Treatment Paradigm

BJU International
Urology
2017English

Pcn144 - Cost-Effectiveness of Cabozantinib for Patients With Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Phase I Clinical Trial of Human Vascular Endothelial Growth Factor Receptor 1 Peptide Vaccines for Patients With Metastatic Renal Cell Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2013English

Spotlight on Cabozantinib for Previously Untreated Advanced Renal Cell Carcinoma: Evidence to Date

Cancer Management and Research
Oncology
2018English

Predicting Postoperative Recurrence of Renal Cell Carcinoma Using Serum Vascular Endothelial Growth Factor

Japanese Journal of Urology
Urology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy